MétaCan
Menu
Back to cohort
Record W2922417594 · doi:10.1093/jcag/gwz006.068

A69 INFLIXIMAB DOSE OPTIMIZATION DURING MAINTENANCE THERAPY IN CHILDREN WITH IBD

2019· article· en· W2922417594 on OpenAlexaff
F. Briglia, Sally Lawrence, Alice Foster, E Briglia, Kevan Jacobson

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2019
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmunodeficiency and Autoimmune Disorders
Canadian institutionsBC Children's Hospital
Fundersnot available
KeywordsInfliximabMaintenance therapyMedicineIntensive care medicineInternal medicineTumor necrosis factor alphaChemotherapy

Abstract

fetched live from OpenAlex

Inflammatory bowel disease (IBD) activity has historically been monitored based on symptoms and disease activity indices. Recently a “treat to target” strategy was reported to be associated with better outcomes. Optimizing biologic therapy based on Therapeutic Drug Monitoring (TDM) is becoming standard of care for management of IBD patients. However, there are limited data on serum infliximab (IFX) trough levels in Pediatric IBD patients on maintenance therapy To evaluate the impact of IFX dose optimization during maintenance therapy in children A chart review of patients on IFX at BC Children’s Hospital was performed. Demographics, CRP, ESR, albumin, PUCAI/PCDAI were recorded along with low IFX trough levels (baseline), and new trough levels following dose adjustments. A request for trough level was determined by the treating physician based clinically and by standard biomarkers of inflammation. Comparison was made between laboratory findings pre and post dose adjustment. A low IFX trough level was defined as serum level <5mg/mL. A patient was considered on maintenance therapy beyond week 14 or after dose #4. The data were analyzed using a t-test and x2 and a p<0.05 was considered significant One hundred and fifty-one active patients who received their first IFX infusion between Nov/08 and Jan/18 were reviewed. Forty-five patients (22.5%; 34 Crohn Disease (CD) and 11 Ulcerative Colitis (UC)) with low trough levels (<5mg/mL) on maintenance were identified. Median age at diagnosis was 10 years (IQR 8–12); Paris classification CD: A1b (73.5%) L3 (50%) L2 (41.2%) L1 (2.9%) L4a (17.6%) L4b (11.8%) p(41.2%) and B1 (97%), UC: E4 (63.6%) E3 (18.2%) and E2 (18.2%). Concomitant therapy in 82% of patients (Methotrexate 48.6%, Azathioprine 51.4%). The median number of IFX doses at baseline was 15 (IQR 10–30), median dose (mg/kg) 7.8 (IQR 5–10) with dosing interval of 7 weeks (SD 1.23). Baseline trough level was 1.9 (SD 0.97). Request for IFX trough level was based on clinical (31.1%), biochemical (31.1%) and both clinical and biochemical findings (37.8%). Ninety eight percent of patients had dose adjustments (increase dose, decreased interval, or both) with a 6.2-fold increase in trough levels (see table) This was associated with an 18.2% incremental increase in remission rate and further 11% reduction in disease activity Optimizing IFX therapy through TDM during maintenance is beneficial for children with IBD. A higher rate of remission was achieved following dose adjustments in patients with low trough levels None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.003
GPT teacher head0.171
Teacher spread0.169 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of GastroenterologySame topicImmunodeficiency and Autoimmune DisordersFrench-language works237,207